Floatz logo

Levofolinic Acid

Esophageal Squamous Cell Carcinoma

Taiho Oncology, Inc.Small moleculePhase 3Active
BB
64/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
52/ 100
Competitive Position
89/ 100

Competitive context

63 Active assets in the Esophageal Squamous Cell Carcinoma cohort.

Asset / SponsorPhaseRating
Xaliplatin
Taiho Oncology, Inc.
Phase 3BB
Fluorouracilum
AstraZeneca
Phase 3BB
Irinotecan
Taiho Oncology, Inc.
Phase 2BB
Cetuximab
Hummingbird Bioscience
Phase 2B
Pembrolizumab
GV20 Therapeutics
Phase 3B

View all 50 →

Same molecule, other indications

Levofolinic Acid is also rated in:

gastroesophageal junction adenocarcinomaActive
BB
Indicative · Phase 3
68 / 100
View asset →
colorectal cancerActive
BB
Indicative · Phase 3
68 / 100
View asset →
colon adenocarcinomaActive
BB
Indicative · Phase 3
64 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →